343 Participants Needed

Tivozanib + Nivolumab for Kidney Cancer

Recruiting at 189 trial locations
CM
AC
Overseen ByAVEO Clinical Trials Office
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: AVEO Pharmaceuticals, Inc.
Must be taking: Immune checkpoint inhibitors
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, it does mention that participants must have recovered from the side effects of previous treatments, which might imply some changes to your current medication regimen.

What data supports the effectiveness of the drug combination Tivozanib and Nivolumab for kidney cancer?

Research shows that Nivolumab, an immune system-boosting drug, improves survival in patients with advanced kidney cancer, and Tivozanib has been found to significantly delay cancer progression compared to another drug, Sorafenib. These findings suggest that combining these drugs could be effective for treating kidney cancer.12345

Is the combination of Tivozanib and Nivolumab safe for humans?

There is safety data available for Nivolumab, which has been used in combination with other drugs for kidney cancer. Studies have shown that Nivolumab, when combined with other treatments, has a manageable safety profile, meaning that while there can be side effects, they are generally considered controllable.678910

What makes the drug combination of Tivozanib and Nivolumab unique for kidney cancer?

The combination of Tivozanib and Nivolumab is unique because Tivozanib is a highly selective VEGFR inhibitor that targets blood vessel growth in tumors, while Nivolumab is an immune checkpoint inhibitor that helps the immune system attack cancer cells. This combination aims to improve treatment effectiveness by using two different mechanisms to fight kidney cancer.24111213

What is the purpose of this trial?

This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).

Eligibility Criteria

This trial is for adults with advanced kidney cancer who've had 1 or 2 previous treatments, including an immune therapy. They must have clear cell renal carcinoma, measurable disease, be in good physical condition (able to perform daily activities), and use contraception. Excluded are those with active autoimmune diseases, uncontrolled high blood pressure, more than one prior immune therapy in the metastatic setting, severe past reactions to immune therapies, certain treatment sequences or over two lines of prior therapy.

Inclusion Criteria

I have recovered from previous treatment side effects to my normal or mild condition.
My kidney cancer has been confirmed with a lab test.
You have a measurable disease according to specific medical guidelines.
See 3 more

Exclusion Criteria

I've had a TKI as my first treatment and an ICI as my second for advanced cancer.
My high blood pressure is not under control.
I have an active autoimmune disease or stopped IO therapy due to side effects.
See 4 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

4 weeks
1 visit (in-person)

Treatment

Participants receive tivozanib with or without nivolumab for 3 weeks followed by 1 week off, repeated in cycles until disease progression or unacceptable toxicity

Approximately 30 months
Monthly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

30 days
1 visit (in-person)

Long-term Follow-up

Participants are monitored for overall survival and progression-free survival

Approximately 42 months

Treatment Details

Interventions

  • Nivolumab
  • Tivozanib
Trial Overview The study compares a combination of Tivozanib (a drug that targets tumor blood vessels) and Nivolumab (an immunotherapy) versus just Tivozanib alone in patients with advanced Renal Cell Carcinoma. It aims to see if adding Nivolumab improves outcomes for patients who have already tried other treatments.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Tivozanib in Combination with NivolumabExperimental Treatment2 Interventions
Subjects with advanced RCC will receive 0.89 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug and nivolumab every 4 weeks on Day 1 of each Cycle, until disease progression or unacceptable toxicities occur, other withdrawal criteria are met, or completion of 2 years of treatment \[for nivolumab\] whichever occurs first.
Group II: TivozanibExperimental Treatment1 Intervention
Subjects with advanced RCC will receive 1.34 mg of tivozanib once daily (QD) for 3 weeks followed by 1 week off study drug until disease progression or unacceptable toxicities occur, or other withdrawal criteria are met.

Nivolumab is already approved in United States, European Union, Canada, Switzerland for the following indications:

🇺🇸
Approved in United States as Opdivo for:
  • Advanced or metastatic gastric cancer
  • Gastroesophageal junction cancer
  • Esophageal adenocarcinoma
  • Melanoma
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Hodgkin lymphoma
  • Head and neck squamous cell carcinoma
  • Urothelial carcinoma
  • Colorectal cancer
  • Hepatocellular carcinoma
  • Esophageal squamous cell carcinoma
🇪🇺
Approved in European Union as Opdivo for:
  • Melanoma
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Hodgkin lymphoma
  • Head and neck squamous cell carcinoma
  • Urothelial carcinoma
  • Colorectal cancer
  • Gastric cancer
  • Gastroesophageal junction cancer
  • Esophageal adenocarcinoma
🇨🇦
Approved in Canada as Opdivo for:
  • Melanoma
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Hodgkin lymphoma
  • Head and neck squamous cell carcinoma
  • Urothelial carcinoma
  • Colorectal cancer
  • Gastric cancer
  • Gastroesophageal junction cancer
  • Esophageal adenocarcinoma
🇨🇭
Approved in Switzerland as Opdivo for:
  • Melanoma
  • Non-small cell lung cancer
  • Renal cell carcinoma
  • Hodgkin lymphoma
  • Head and neck squamous cell carcinoma
  • Urothelial carcinoma
  • Colorectal cancer
  • Gastric cancer
  • Gastroesophageal junction cancer
  • Esophageal adenocarcinoma

Find a Clinic Near You

Who Is Running the Clinical Trial?

AVEO Pharmaceuticals, Inc.

Lead Sponsor

Trials
46
Recruited
4,000+

Parexel

Industry Sponsor

Trials
322
Recruited
137,000+
Peyton Howell profile image

Peyton Howell

Parexel

Chief Executive Officer

Master of Healthcare Administration from The Ohio State University, Bachelor of Arts in Health Communications from the University of Illinois

Dr. Austin Smith profile image

Dr. Austin Smith

Parexel

Chief Medical Officer since 2023

MD from the Royal College of Surgeons in Ireland

Bristol-Myers Squibb

Industry Sponsor

Trials
2,731
Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia
Christopher Boerner profile image

Christopher Boerner

Bristol-Myers Squibb

Chief Executive Officer since 2023

PhD in Business Administration from the Haas School of Business, University of California, Berkeley; BA in Economics and History from Washington University in St. Louis

Deepak L. Bhatt profile image

Deepak L. Bhatt

Bristol-Myers Squibb

Chief Medical Officer since 2024

MD from Yale University; MSc in Clinical Epidemiology from the University of Pennsylvania

Findings from Research

A 65-year-old man with advanced renal cell carcinoma achieved a remarkable reduction in metastasis after receiving nivolumab as the fifth systemic therapy, following treatment with angiogenesis inhibitors and interferon-α.
The patient experienced a pathological complete response, with no cancer cells found after adrenalectomy, and remains healthy 20 months post-surgery, highlighting the potential efficacy of nivolumab in advanced renal cell carcinoma cases.
Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma.Hagimoto, H., Kashima, S., Doi, K., et al.[2022]
Nivolumab (Opdivo®) has been established as an effective second-line treatment for metastatic renal cell carcinoma (mRCC), showing improved overall survival (26 months vs. 19.7 months) and response rates compared to Everolimus, based on the CheckMate 025 trial with 1,080 participants.
The combination of Nivolumab and Ipilimumab has demonstrated a significantly higher objective response rate (42% vs. 27%) and better overall survival in intermediate and high-risk patients compared to Sunitinib, while also improving quality of life, despite an increase in immune-related adverse events.
[Immunotherapy for renal cell carcinoma - current status].Grimm, MO., Foller, S.[2019]
Nivolumab, when combined with ipilimumab, significantly improves overall survival (OS) and progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC), based on a meta-analysis of three high-quality randomized controlled trials involving 2550 patients.
The treatment with nivolumab did not lead to an increase in adverse events, indicating a manageable safety profile for patients undergoing this therapy.
Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.Zhang, S., Xu, X., Chen, J., et al.[2022]

References

Pathological complete response after nivolumab therapy following angiogenesis inhibitors in a patient with metastatic renal cell carcinoma. [2022]
[Immunotherapy for renal cell carcinoma - current status]. [2019]
Efficacy and Safety of Nivolumab for Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. [2022]
Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC. [2021]
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. [2022]
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme. [2022]
Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab. [2023]
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. [2022]
Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up. [2020]
10.United Statespubmed.ncbi.nlm.nih.gov
Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study. [2023]
TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma. [2021]
Tivozanib: First Global Approval. [2018]
Tivozanib: a novel VGFR inhibitor for kidney cancer. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security